Invivyd, Inc. financial data

Symbol
IVVD on Nasdaq
Industry
Biological Products, (No Diagnostic Substances)
Location
1601 Trapelo Road, Suite 178, Waltham, MA
State of incorporation
DE
Fiscal year end
December 31
Former names
Adagio Therapeutics, Inc. (to 9/12/2022)
Latest financial report
10-Q - Q3 2024 - Nov 14, 2024

Key Ratios

Label TTM Value / Value Unit Change %
Current Ratio 376 % -69.3%
Quick Ratio 16.1 %
Debt-to-equity 35.2 % +276%
Return On Equity -155 % -177%
Return On Assets -115 % -124%

Shares

Label TTM Value / Value Unit Change %
Entity Common Stock, Shares Outstanding 120M shares +8.63%
Common Stock, Shares, Outstanding 120M shares +8.88%
Entity Public Float 67.1M USD -70.6%
Common Stock, Value, Issued 12K USD +9.09%
Weighted Average Number of Shares Outstanding, Basic 119M shares +8.88%
Weighted Average Number of Shares Outstanding, Diluted 119M shares +8.88%

Income Statement

Label TTM Value / Value Unit Change %
Revenues 9.3M USD
Research and Development Expense 182M USD +56.1%
Costs and Expenses 71.6M USD +66.3%
Operating Income (Loss) -234M USD -27.2%
Nonoperating Income (Expense) 9.26M USD -36.8%
Income Tax Expense (Benefit) 0 USD
Net Income (Loss) Attributable to Parent -225M USD -32.8%
Earnings Per Share, Basic -1.96 USD/shares -26.5%
Earnings Per Share, Diluted -1.96 USD/shares -26.5%

Balance Sheet

Label TTM Value / Value Unit Change %
Cash and Cash Equivalents, at Carrying Value 107M USD -41.2%
Accounts Receivable, after Allowance for Credit Loss, Current 8.15M USD
Inventory, Net 27.1M USD
Assets, Current 151M USD -44.1%
Property, Plant and Equipment, Net 1.64M USD -18.1%
Operating Lease, Right-of-Use Asset 1.73M USD -34.1%
Other Assets, Noncurrent 7.45M USD +3885%
Assets 162M USD -41.1%
Accounts Payable, Current 17.7M USD +93.1%
Accrued Liabilities, Current 59.4M USD +272%
Liabilities, Current 78.5M USD +193%
Operating Lease, Liability, Noncurrent 219K USD -76.4%
Other Liabilities, Noncurrent 0 USD -100%
Liabilities 78.8M USD +177%
Accumulated Other Comprehensive Income (Loss), Net of Tax -18K USD -800%
Retained Earnings (Accumulated Deficit) -884M USD -34.2%
Stockholders' Equity Attributable to Parent 83.2M USD -66.3%
Liabilities and Equity 162M USD -41.1%

Popular Metrics

Label TTM Value / Value Unit Change %
Net Cash Provided by (Used in) Operating Activities -50.2M USD -21.9%
Net Cash Provided by (Used in) Financing Activities 39.1M USD +7114%
Net Cash Provided by (Used in) Investing Activities -140K USD -100%
Common Stock, Shares Authorized 1B shares 0%
Common Stock, Shares, Issued 120M shares +8.88%
Common Stock, Par or Stated Value Per Share 0 USD/shares 0%
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect -11.3M USD -133%
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents 107M USD -41.2%
Deferred Tax Assets, Valuation Allowance 200M USD +52.6%
Deferred Tax Assets, Gross 201M USD +52.1%
Operating Lease, Liability 435K USD +0.69%
Depreciation 122K USD +1.67%
Payments to Acquire Property, Plant, and Equipment 140K USD -77.6%
Comprehensive Income (Loss), Net of Tax, Attributable to Parent -225M USD -32.7%
Lessee, Operating Lease, Liability, to be Paid 1.69M USD
Operating Lease, Liability, Current 1.41M USD -13.7%
Lessee, Operating Lease, Liability, to be Paid, Year Two 421K USD
Lessee, Operating Lease, Liability, to be Paid, Year One 411K USD
Lessee, Operating Lease, Liability, to be Paid, Year Three 430K USD
Deferred Tax Assets, Operating Loss Carryforwards 76.4M USD +24%
Preferred Stock, Shares Issued 0 shares
Preferred Stock, Shares Authorized 10M shares 0%
Lessee, Operating Lease, Liability, to be Paid, Year Four 328K USD
Operating Lease, Payments 435K USD +0.69%
Preferred Stock, Shares Outstanding 0 shares
Deferred Tax Assets, Net of Valuation Allowance 699K USD -21.9%
Share-based Payment Arrangement, Expense 21.1M USD +4.11%
Operating Leases, Future Minimum Payments Due 108M USD
Preferred Stock, Par or Stated Value Per Share 0 USD/shares 0%